drugset / Trial / NCT01670994
QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase Ib/II, open-label, multi-center and competitive enrollment study of ALT-801 in patients who have relapsed or refractory multiple myeloma.
Timeline
- Start
- 2012-08-14
- Primary completion
- 2015-09-09
- Completion
- 2015-09-09
Outcome
Outcome not reported
Stopped: “Patient population did not benefit from single agent treatment.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ALT-801 | Protein / enzyme biologic | 0.04 mg/kg | Intravenous |
| Subject | ALT-801 | Protein / enzyme biologic | 0.06 mg/kg | Intravenous |